{"id":526,"date":"2022-10-17T14:33:56","date_gmt":"2022-10-17T14:33:56","guid":{"rendered":"http:\/\/www.colo-check.com\/?page_id=526"},"modified":"2026-06-10T14:05:30","modified_gmt":"2026-06-10T14:05:30","slug":"home-page","status":"publish","type":"page","link":"http:\/\/www.colo-check.com\/en\/","title":{"rendered":"Home Page"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n \t\t
\n\t\t\t\t\t\r\n\r\n
\r\n
\r\n
\r\n
\r\n
\r\n
<\/span>Early diagnosis in colorectal cancer<\/div>\r\n

\r\n Comfortable, fast, reliable early diagnosis<\/strong>\r\n <\/h1>\r\n

\r\n Colo-Check offers a patient-friendly and molecular-based early diagnosis solution in colorectal cancer screening, allowing patients to provide samples without the invasive burden of colonoscopy.\r\n <\/p>\r\n

\r\n Explore the Technology<\/a>\r\n View Performance<\/a>\r\n <\/div>\r\n

\r\n Patients with a positive test result are referred for colonoscopy; in patients with a negative result, the aim is to reduce unnecessary invasive procedures.\r\n <\/p>\r\n <\/div>\r\n\r\n

\r\n
\r\n \r\n \"Visual\r\n <\/div>\r\n
\r\n

Dual matrix panel approach<\/p>\r\n Stool + Serum<\/span>\r\n <\/div>\r\n

\r\n
\r\n G<\/span>\r\n

Stool analysis<\/h3>\r\n

Screening of epigenetic cancer traces with a 6-gene panel.<\/p>\r\n <\/div>\r\n

\r\n S<\/span>\r\n

Serum analysis<\/h3>\r\n

Supportive confirmation from a blood sample with a 3-gene panel.<\/p>\r\n <\/div>\r\n <\/div>\r\n

\r\n %90,6<\/span>\r\n

Sensitivity<\/h3>\r\n

Performance reported in dual-matrix clinical study data.<\/p>\r\n <\/div>\r\n <\/div>\r\n <\/div>\r\n\r\n

\r\n
\r\n %90,0<\/strong>\r\n Dual matrix panel specificity<\/span>\r\n <\/div>\r\n
\r\n %90<\/strong>\r\n Strong detection target in early stages<\/span>\r\n <\/div>\r\n
\r\n Non<\/strong>\r\n Invasive sample collection process<\/span>\r\n <\/div>\r\n
\r\n 7-8h<\/strong>\r\n Optimized laboratory analysis process<\/span>\r\n <\/div>\r\n <\/div>\r\n <\/div>\r\n <\/section>\r\n\r\n
\r\n
\r\n
\r\n
\r\n

Hybrid molecular solution<\/p>\r\n

Dual matrix technology that does not depend on a single sample type<\/h2>\r\n

\r\n The distinctive aspect of Colo-Check is its ability to simultaneously analyze both stool and serum samples taken from the same patient. This approach helps evaluate epigenetic cancer traces through cross-validation.\r\n <\/p>\r\n <\/div>\r\n\r\n

\r\n
\r\n

Stool analysis only<\/h3>\r\n

Provides 80.0% sensitivity and 93.7% specificity data with a 6-gene panel.<\/p>\r\n <\/article>\r\n

\r\n

Serum analysis only<\/h3>\r\n

Provides 75.7% sensitivity and 94.3% specificity data with a 3-gene panel.<\/p>\r\n <\/article>\r\n

\r\n

Stool + serum panel<\/h3>\r\n

Reaches 90.6% sensitivity and 95.0% specificity with the dual matrix approach.<\/p>\r\n <\/article>\r\n <\/div>\r\n <\/div>\r\n <\/div>\r\n <\/section>\r\n

\r\n
\r\n